Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study

BACKGROUND: MET amplification or METex14 skipping mutations are uncommon oncogenic events in NSCLC patients. Clinicopathological characteristics, concurrent gene alterations, and prognosis of MET TKIs in these patients are yet to be elucidated. METHODS: We retrospectively analyzed the genomic profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Li, Kalyani, Farhin Shaheed, Yang, Haiyan, Zhou, Chunhua, Xiong, Yi, Zhu, Songlin, Yang, Nong, Qu, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264054/
https://www.ncbi.nlm.nih.gov/pubmed/34249687
http://dx.doi.org/10.3389/fonc.2021.649766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264054/
https://www.ncbi.nlm.nih.gov/pubmed/34249687
http://dx.doi.org/10.3389/fonc.2021.649766

Ejemplares similares